Lung Cancer
Conditions
Brief summary
A retrospective observational longitudinal medical chart review study of randomly sampled patients diagnosed with advanced/metastatic NSCLC. The minimum observational period for each patient will be 12 months.
Interventions
None listed
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults 18 years and older at the time of advanced/metastatic NSCLC diagnosis, and currently alive or deceased * Histologically confirmed diagnosis of advanced/metastatic NSCLC (squamous, non-squamous or NOS) stages IIIB/IV. First diagnosis of advanced/metastatic NSCLC between 01-Jan-2010 and 31-Mar-2014 (currently alive or deceased) with a minimum 12 months of potential observation period available in medical records * Medical history and treatment data must be available (or obtainable by SI) for chart abstraction from the date of advanced/metastatic diagnosis through most recent patient follow-up/contact. This also includes documentation of treatment by other physicians and inpatient hospital treatments within KSA or the Health Authority of Abu Dhabi (HAAD) system * Patients must have at least all data on age, gender, date of advanced NSCLC diagnosis, Line of Treatment (LOT) information (agent types and dosage), and date of last follow-up
Exclusion criteria
* Patient had enrolled in a cancer treatment-related clinical study at any time after the diagnosis of advanced/metastatic NSCLC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution of reasons for discontinuing treatment | approximately 12 months |
| Patient Demographics at diagnosis with advanced/metastatic NSCLC | at baseline |
| Systemic treatments prescribed for NSCLC patients from treatment initiation through discontinuation | approximately 12 months |
| Duration of systemic treatments | approximately 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| healthcare resource utilization in patients with advanced/metastatic NSCLC | approximately 12 months | NSCLC-related health care resources associated with the provision of systemic treatments and managing side effects of treatments: hospital admissions including emergency room visits |
| Progression-Free Survival (PFS) | approximately 12 months | — |
| Overall Survival (OS) | approximately 12 months | — |
| Adverse Events (AEs) | approximately 12 months | — |
Outcome results
None listed